Controversy and consensus of the anti-tumor necrosis factor alpha in the treatment of Crohn's disease with intestinal stricture
10.3760/cma.j.issn.1673-9752.2018.09.006
- VernacularTitle:抗肿瘤坏死因子-α抗体治疗狭窄型克罗恩病的争议与共识
- Author:
Qiao YU
1
;
Qinghai LI
;
Yongmao SONG
;
Dong XU
;
Yan CHEN
Author Information
1. 浙江大学医学院附属第二医院消化内科
- Keywords:
Crohn's disease;
Anti-tumor necrosis factor alpha;
Infliximab;
Intestinal stricture
- From:
Chinese Journal of Digestive Surgery
2018;17(9):905-909
- CountryChina
- Language:Chinese
-
Abstract:
The emergence of the anti-tumor necrosis factor alpha(anti-TNF-α)therapies has brought lots of benefits to patients with inflammatory bowel disease(IBD).However,controversies exist over whether anti-TNF-α could be used for Crohn's disease(CD)patients with intestinal stricture.Some articles found stricturing CD patients under anti-TNF therapy had a high risk of intestinal obstruction or even perforation while others found that there was no association between anti-TNF-α and intestinal obstruction.The fundamental cause lies in that anti-TNF-α only target at inflammation,but cannot be resistant to intestinal fibrosis or change long term outcome.To avoid and prevent intestinal obstruction or perforation,authors should evaluate the component and type of intestinal stricture cautiously before starting anti-TNF-α therapy.Exploring new specific antifibrotic therapy will be a promising way for all stricturing CD patients.
